Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04909346 · ClinicalTrials.gov registry record
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 51
- Enrollment target
NCT04909346 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 51 participants.
The verdict
NCT04909346 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
The objective of this observational study is to evaluate the seroprevalence of anti-AAV antibodies in subjects with Ornithine Transcarbamylase (OTC) deficiency, Glycogen Storage Disease Type Ia (GSDIa), and Wilson Disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-06-23 |
| Est. Completion | 2022-11-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04909346
The ClinicalTrials.gov registry entry for NCT04909346 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04909346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04909346 about?
NCT04909346 is a clinical study titled "Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease". The objective of this observational study is to evaluate the seroprevalence of anti-AAV antibodies in subjects with Ornithine Transcarbamylase (OTC) deficiency, Glycogen Storage Disease Type Ia (GSDIa), and Wilson Disease
What is the current status of trial NCT04909346?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2021-06-23. Estimated completion is 2022-11-17.
Who is sponsoring clinical trial NCT04909346?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.